Michael Rippee, MD

Sports Neurologist and Medical Director for the Center for Concussion Management at the University of Kansas Health System

[Oxeia Biopharma @oxeiabio]

3 days. If you haven't registered yet—here's the short version:

Michael Wyand. Vishal Bansal. Alex Smith.

A live conversation on why ghrelin may be the key to treating concussion, what the Phase 2a data showed, and what Phase 2b is designed to prove. This is the conversation for anyone following this campaign closely.

📅 Thursday, June 18 · 11 AM PT / 2 PM ET

Reserve your spot: https://t.co/YkSOUtx4GT

OXE103 is investigational. Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Michael Rippee, MD @MichaelRippee]

Don't forget to register now for the 8th annual #concussion symposium. Just 1 month away--Friday, April 3rd. Click the link to register! Check out the full schedule with great speakers!
https://t.co/wUbI28tLCR
@KU_AHEC @KUSportsMed @KUMedCenter @KUHospital @BBlissDPT

[Michael Rippee, MD @MichaelRippee]

Only 1 month away! 8th annual #concussion symposium @KUHospital @KUSportsMed @KUMedCenter Friday, April 3rd. Link to register is below. Click to see agenda including (Dr. Doug Terry @VUMChealth, @DavisSLP, @BBlissDPT
https://t.co/zy8pgG8xXr

[Michael Rippee, MD @MichaelRippee]

Registration is open for the 8th annual #concussion symposium @KUHospital @KUMedCenter @KUSportsMed Friday, April 3rd. Click the link to register and see the amazing speakers lined up. (Dr. Doug Terry @VUMChealth , @DavisSLP, @BBlissDPT)
https://t.co/zy8pgG8xXr

[Oxeia Biopharma @oxeiabio]

We launched our StartEngine campaign to advance OXE103, a therapy for persistent #concussion symptoms.

What could be the first FDA-approved treatment.

https://t.co/mKsdkzk3E7
Reg CF via StartEngine Primary, LLC (FINRA/SIPC). High Risk, Speculative, Illiquid.

[Oxeia Biopharma @oxeiabio]

Hear NFL legend @AlexSmith_11 talk concussions on podcast with @oxeiabio CSO on Wednesday evening. Exploring possible new treatments to combat #Concussion Crisis. https://t.co/3SP7mJz2Ek

[Oxeia Biopharma @oxeiabio]

Former NFL pro @AlexSmith_11 joining @oxeiabio CSO Vishal Bansal for podcast on #brain injury, #football concussions and hope for future treatment this Wednesday, January 7. https://t.co/3SP7mJz2Ek

[Oxeia Biopharma @oxeiabio]

The concussion market forecasted to expand steadily, reaching $9.9 billion by 2029 according to @tbrc_info. Rise in awareness and management of #brain injuries are cited as major drivers.  @oxeiabio featured as a projected major player in market growth. https://t.co/TnCSQ9Vaqb

[Oxeia Biopharma @oxeiabio]

Researchers from @Sunnybrook Research Institute and @ICESOntario reported in @BMJ_Open that people with #concussions were almost 50% more likely to be in a traffic crash and that the increased risk is highest in the first four weeks after their #TBI. https://t.co/FkbZ220Kfl

[STAT @statnews]

“This is not just about one device. It’s about what happens when institutions grow comfortable living in their own ambiguity and hiding behind opacity.” https://t.co/RQWSDh8DIz

[Michael Rippee, MD @MichaelRippee]

So great to talk about #concussion and our multi-disciplinary team @KUHospital as well as our research @oxeiabio Appreciate @KUHospitalNews for highlighting this!

[Michael Rippee, MD @MichaelRippee]

All Things Brain Health - Concussion Treatment with the Hormone Ghrelin https://t.co/U3xL9BIYLj via @YouTube

[Sandra Billinger @Sandy_REACHLab]

Key finding: People w/ worse higher arterial stiffness & higher NfL showed the greatest cognitive deficits—especially in episodic & working memory. @TK_timoklein @J_C_MD_PhD @FannyElahi @NAASociety @VascAgeNet @Barnes_Lab @balkhaz @kevinmoncion @LBeishon @DrJMinhas

[Sandra Billinger @Sandy_REACHLab]

Arterial stiffness moderates the link between NfL and cognition: The IGNITE study,” is now published! Proud to contribute to this project & publication w/ #IGNITE team & our @KUALZ team JillMorris EricVidoni JeffBurns
https://t.co/CyQVUZ4vcz

[Chris Giza @griz1]

Concussive Brain Injury pathophysiology is evolving! Its more than "acute neuro-metabolic" cascade now. #ShaneBR @neuroayogi @MlPrinsPhD @BIRC_at_UCLA @UCLABrainSPORT @UCLANsgy @uclachildneuro @UCLANeurology @Neurotrauma
Learn more (50 days free access): https://t.co/GVucvrPpAR

[Oxeia Biopharma @oxeiabio]

The paper concludes preliminary data for the small non-randomized trial are nevertheless “compelling as a first-in-class treatment for postconcussion symptomatology.” Once we meet funding goals, we’ll be ready to conduct full scale multi-center, placebo controlled Phase 2b study

[Oxeia Biopharma @oxeiabio]

Manuscript recently published by Neurotrauma Reports on pilot Phase IIa trial for treatment of #post-concussion symptoms with Oxeia’s drug, OXE103. The trial was conducted by lead investigator @MichaelRippee at Kansas University Medical Center,: https://t.co/ZQusgONOCr

[Oxeia Biopharma @oxeiabio]

Oxeia CEO Michael Wyand talks with @editorNRTimes, exploring the gap in #TBI and #concussion treatment, the company’s promising results in its  pilot Phase 2a study for #postconcussion treatment and the challenges of finding funding for the next trial. https://t.co/8M7OpdT90L

[Neuro Rehab Times @editorNRTimes]

Despite healthcare seeing incredible advancements over the past decade, the area of concussion and TBI treatment has seen little progress.

We speak to Dr. Michael Wyand, CEO of @oxeiabio about how its new treatment could transform concussion care.

https://t.co/wMOxUmWwyW

[Becky Bliss, PT, DPT, DHSc @BBlissDPT]

Do you work with individuals who have experienced a concussion?
Please consider joining our study at the University of Kansas Medical Center! We're exploring what objective measures are commonly used in concussion management related to motor function!! If you have questions please contact Rebecca Bliss, PT, DPT, DHSc @ [email protected] Learn more and take survey: https://t.co/Wo0FF3lYSg